Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20th 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Q & A and Final Thoughts

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

August 20th 2020

Recent Progress in the Treatment of SCLC

August 20th 2020

Introduction and Identifying Predictive Biomarkers

August 20th 2020

Repotrectinib Elicits Encouraging Response Rates in ROS1- and NTRK-Driven Tumors

August 19th 2020

Treatment with repotrectinib resulted in favorable responses in patients with ROS1- or NTRK-driven tumors, regardless of prior treatment with TKIs, according to interim data from the phase 2 TRIDENT-1 trial.

Dr. Bunn on Targeting HER3 in NSCLC

August 18th 2020

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

FDA Grants Durvalumab Priority Review for Fixed-Dose Use in NSCLC and Bladder Cancer

August 18th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

FDA Grants Trilaciclib Priority Review for Small Cell Lung Cancer

August 17th 2020

The FDA has granted a priority review designation to a new drug application (NDA) for trilaciclib for the treatment of patients with small cell lung cancer (SCLC) who are being treated with chemotherapy.

Future of ALK-rearranged mNSCLC

August 17th 2020

Testing for ALK Rearrangements in mNSCLC

August 17th 2020

Subsequent Lines of Therapy in ALK-rearranged mNSCLC

August 17th 2020

Updates Informing the Management of ALK-rearranged mNSCLC

August 17th 2020

Updates Informing the Management of NTRK+ NSCLC

August 17th 2020